Nigeria Strengthens Drug Safety With US Partnership Deal

Nigeria is taking bold steps to protect its citizens from unsafe medicines while keeping critical HIV/AIDS treatments flowing into the country.

The National Agency for Food and Drug Administration and Control (NAFDAC) announced it will test all donated drugs and vaccines that aren't made in the United States under a new Nigeria-US government agreement. This decision ensures the country maintains full control over what enters its medical supply chain, even as it accepts international support.

US-manufactured drugs already approved by America's FDA can receive faster approval through an existing partnership between the two agencies. But NAFDAC's Director-General, Prof. Mojisola Christianah Adeyeye, made it clear that expedited approval doesn't mean less oversight.

"NAFDAC retains its responsibility for Nigeria's own decision," the agency stated. Products from other countries will go through full quality, safety, and efficacy testing at Nigerian labs.

The agency is backing up its promise with proven technology. NAFDAC will deploy its GS1 Track and Trace system to monitor every medical product that enters the country under the agreement. This same system successfully tracked COVID-19 vaccines during the pandemic and now monitors everything from tuberculosis drugs to maternal health supplies.

The timing matters. This enhanced oversight comes as Nigeria works to sustain HIV/AIDS treatment programs following USAID's exit from the country. The US government agreement aims to bridge that gap, but Nigerian officials want citizens to know safety isn't being compromised for speed.

The Ripple Effect

NAFDAC's track record shows this isn't just talk. During the COVID-19 pandemic, the agency tested every vaccine batch at its Lagos laboratory, even though the World Health Organization had already declared them safe. The agency also tests antiretroviral, tuberculosis, and malaria drugs from the Global Fund annually.

This careful approach to international partnerships could serve as a model for other African nations navigating similar agreements. By combining regulatory efficiency with uncompromised safety standards, Nigeria is showing that countries don't have to choose between accessing critical medicines quickly and protecting their citizens.

The Track and Trace technology adds another layer of protection by creating visibility across the entire supply chain. Health officials can now monitor where medicines go after they enter the country, helping prevent diversion or counterfeit products from entering the system.

For millions of Nigerians who depend on these medicines, particularly those living with HIV/AIDS, the message is reassuring: help is coming, and it will be safe.